Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Sartor, Oliver; S. de Bono, Johann; N., Kim; Fizazi, Karim; Herrmann, Ken; Rahbar, Kambiz; T. Tagawa, Scott; T. Nordquist, Luke; Vaishampayan, Nitin; El‐Haddad, Ghassan; H. Park, Chandler; M. Beer, Tomasz; Armour, Alison; J. Pérez-Contreras, Wendy; DeSilvio, Michelle; Kpamegan, Euloge; Gericke, Germo; A. Messmann, Richard; J. Morris, Michael; J. Krause, Bernd

doi:10.1056/nejmoa2107322

Public

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Published in New England Journal of Medicine • Jun 23, 2021

Authors:

Oliver Sartor

Johann S. de Bono

Kim N.

Abstract

BACKGROUND: Lu)-PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment. METHODS: Ra), and investigational drugs. The alternate primary end points were imaging-based progression-free survival and overall survival, which we...

Subject

Prostate cancer

Medicine

Castration

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!